Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled 160 people in total — 96 received an injection of a drug called CLS-TA delivered into a specific layer at the back of the eye (called a suprachoroidal injection), while 64 underwent a sham (fake) procedure as a comparison group. The trial was primarily measuring how many participants had a meaningful improvement in their vision — specifically, reading at least 15 more letters on an eye chart — after 24 weeks. The reported data shows that in the injection group, 45 out of 96 participants reached that 15-letter improvement mark, compared with 10 out of 64 in the sham group. For a secondary measure, the trial tracked changes in the thickness of the central part of the retina (a layer at the back of the eye) — where a reduction in thickness can indicate less swelling. The reported data shows the injection group had an average reduction of about 153 micrometres (a very small unit of measurement), while the sham group had an average reduction of about 18 micrometres. Regarding reported side effects, 67 of 96 participants in the injection group and 45 of 64 in the sham group experienced at least one treatment-related adverse event (an unwanted health occurrence noted during the study). Serious adverse events were reported in 3 participants in the injection group and none in the sham group. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 36787524) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Uveitis Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with a type of eye inflammation called non-infectious uveitis (this includes inflammation affecting the front, middle, back, or all layers of the eye)
- You have swelling in the central part of your retina (the back of the eye) that is linked to your uveitis, measured at a specific thickness by a scan
- Your vision in the eye being studied is reduced but not completely gone — roughly between being able to read the big "E" on an eye chart and seeing clearly at about arm's length (confirm exact vision levels with trial site)
Who may not be able to join:
- You have another active eye disease or eye infection in the eye being studied, separate from your uveitis
- The pressure inside your eye is too high or your glaucoma is not well controlled (though you may still qualify if your eye pressure is within an acceptable range and you use no more than two pressure-lowering medications)
- You have another serious health condition that is not well controlled and that the trial doctor feels would make it unsafe for you to participate
- You have used certain steroid treatments in or around your eye recently — this includes steroid eye drops within the last 10 days, steroid injections within the last 2 months, or certain longer-acting steroid implants within the last 6 months to 3 years depending on the type (confirm specific details with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of Subjects Demonstrating ≥ 15 Letter Improvement From Baseline in Best Corrected Visual Acuity at 24 Weeks
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.